Subject(s)
Cranial Fossa, Posterior , Pneumocephalus/diagnostic imaging , Aged , Cranial Fossa, Posterior/diagnostic imaging , Cranial Fossa, Posterior/pathology , Female , Humans , Mastoid/diagnostic imaging , Pneumocephalus/pathology , Pneumocephalus/surgery , Temporal Bone/diagnostic imaging , Tomography, X-Ray Computed , Vestibular Aqueduct/diagnostic imagingABSTRACT
Hearing loss affects approximately 30 million people in the United States. It has been estimated that only approximately 20% of people with hearing loss significant enough to warrant amplification actually seek assistance for amplification. A significant interest in middle ear implants has emerged over the years to facilitate patients who are noncompliant with conventional hearing aides, do not receive significant benefit from conventional aides, or are not candidates for cochlear implants. From the initial studies in the 1930s, the technology has greatly evolved over the years with a wide array of devices and mechanisms employed in the development of implantable middle ear hearing devices. Currently, these devices are generally available in two broad categories: partially or totally implantable using either piezoelectric or electromagnetic systems. The authors present an up-to-date overview of the major implantable middle ear devices. Although the current devices are largely in their infancy, indications for middle ear implants are ever evolving as promising studies show good results. The totally implantable devices provide the user freedom from the social and practical difficulties of using conventional amplification.
Subject(s)
Correction of Hearing Impairment , Hearing Loss/surgery , Ossicular Prosthesis , Persons With Hearing Impairments/rehabilitation , Prosthesis Implantation , Acoustic Stimulation , Electromagnetic Phenomena , Hearing Loss/rehabilitation , History, 20th Century , History, 21st Century , Humans , Ossicular Prosthesis/history , Patient Compliance , Prosthesis Design , Signal Processing, Computer-AssistedABSTRACT
Intratracheal instillation of perfluorochemical (PFC) liquids enhances lung epithelial transgene expression by improved vector propulsion throughout lung airways. We now demonstrate that PFC liquids also facilitate gene transfer by increasing transepithelial permeability. Apical application of PFC liquid to well-differentiated human airway epithelial cells resulted in a transient decrease in transepithelial resistance peaking approximately 2 h after PFC liquid administration and returning to normal approximately 24 h later. The permeability change was sufficient to enhance access of apically applied 100-nm latex beads and adenoviral vectors to the basolateral side of the culture. Adenovirus-mediated gene expression was concurrently enhanced. Following intratracheal instillation of PFC liquid into mouse lungs, tight junction permeability, as assessed by electron microscopic evaluation of lanthanum deposition, was increased with peak effect between 6 h and 1 day after instillation. Importantly, alveolar-capillary permeability remained unchanged with the treatment. Administration of PFC liquid 6 h or 1 day, but not 3 days, prior to instillation of a recombinant adenovirus vector enhanced gene expression comparable to that observed with concurrent administration of PFC liquid and vector. We conclude that transient increase in epithelial permeability after PFC liquid administration contributes to the enhancement of adenovirus vector-mediated gene expression in lung epithelium.